Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Esophageal Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Pathologic Complete Response 2Fallopian Tube Neoplasms 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thymoma 1Testicular Neoplasms 1Recurrence 1Ovarian Neoplasms 1Non-squamous Cell Non-Small Cell Lung Cancer 1Non-Squamous Non-Small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Lung Neoplasms 1HER2 Positive Breast Cancer 1Endometrial Neoplasms 1EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Ovarian Epithelial 1

Interventions

pyrotinib 2Trastuzumab 2Vinorelbine 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × HER2 Positive Breast Cancer × Carboplatin × Clear all
NCT03735966 2022-12-01

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.

Henan Cancer Hospital

Phase 2 Completed
75 enrolled
Breast

HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡